BioSyntech, Inc. Engages in the development of bio-therapeutic thermogels designed for tissue repair and delivery of therapeutic agents. The company is headquartered in Laval, Quebec and currently employs 20 full-time employees. The company went IPO on 2000-01-10. The firm is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The firm's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The firm's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.
